Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

INTRODUCTION: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity in early clinical trials; however, their efficacy in the real-world setting is unknown. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Illini, Oliver, Hochmair, Maximilian Johannes, Fabikan, Hannah, Weinlinger, Christoph, Tufman, Amanda, Swalduz, Aurélie, Lamberg, Kristina, Hashemi, Sayed M. S., Huemer, Florian, Vikström, Anders, Wermke, Martin, Absenger, Gudrun, Addeo, Alfredo, Banerji, Shantanu, Calles, Antonio, Clarke, Stephen, Di Maio, Massimo, Durand, Alice, Duruisseaux, Michaël, Itchins, Malinda, Kääränien, Okko-Sakari, Krenn, Florian, Laack, Eckart, de Langen, Adrianus Johannes, Mohorcic, Katja, Pall, Georg, Passaro, Antonio, Prager, Gerald, Rittmeyer, Achim, Rothenstein, Jeffrey, Schumacher, Michael, Wöll, Ewald, Valipour, Arschang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Advances in Treatment of Lung Cancer Patients with Targetable Mutations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202258/
https://www.ncbi.nlm.nih.gov/pubmed/34178121
http://dx.doi.org/10.1177/17588359211019675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202258/
https://www.ncbi.nlm.nih.gov/pubmed/34178121
http://dx.doi.org/10.1177/17588359211019675

Ejemplares similares